The European Medicines Agency has accepted for review marketing authorization applications (MAAs) for eight new drugs and has agreed to fast track its assessment for three of them.
The MAAs granted accelerated assessment are for Novimmune’s emapalumab*, for treating children with primary hemophagocytic lymphohistiocytosis (HLH), Theratechnologies/TaiMed Biologics’ multidrug...








